vincristine (PCV) chemotherapy in chemotherapy to newly diagnosed radiotherapy (RT) (368 anaplastic patients, median oligodendroglioma: long-term follow-up follow-up 140 months) of EORTC brain In the 80 patients with tumor group study a 1p/19q codeletion, 26951. J Clin Oncol. OS was increased, 2013;31(3):344-50. demonstrating benefit of adjuvant PCV with RT. IDH mutational status was also of prognostic significance. 5. Meta analysis A systematic review 2016 Hu N, Richards R, and meta-analysis on Jensen R. Role of the prognostic effect of chromosomal 1p/19q co-deletion 1p/19q co-deletion on the prognosis of affects prognoses of oligodendrogliomas WHO grade II/III A systematic oligodendrogliomas. review and The study demonstrated the Interdisciplinary beneficial prognosis of Neurosurgery. chromosomal 1p/19q 2016;5:58-63. co-deletion in these tumours. 6. Observational of actionable 2016 Staedtke V, Dzaye study biomarkers available in ODA, Holdhoff M. the diagnosis of brain Actionable Molecular tumours. (i) MGMT Biomarkers in promoter methylation Primary Brain as a prognostic and Tumors. Trends predictive marker in Cancer. glioblastoma; (ii) 2016;2(7):338-49. codeletion of 1p and 19q differentiating from astrocytomas; (iii) IDH1/2 mutations; and (iv) select mutations. 7. Observational Rare Cancers A review of available 2016 study Australia: Just a cancer data Little More Time investigating the Rare Cancers disparities existing for Update Report. incidence, mortality 2016 and survival across the cancer spectrum. The study provided a definition for rare
chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-50. vincristine (PCV) chemotherapy to radiotherapy (RT) (368 patients, median follow-up 140 months) In the 80 patients with a 1p/19q codeletion, OS was increased, demonstrating benefit of adjuvant PCV with RT. IDH mutational status was also of prognostic significance. 5. Meta analysis Hu N, Richards R, Jensen R. Role of chromosomal 1p/19q co-deletion on the prognosis of A systematic review and Interdisciplinary Neurosurgery. 2016;5:58-63. A systematic review and meta-analysis on the prognostic effect of 1p/19q co-deletion affects prognoses of WHO grade II/III oligodendrogliomas. The study demonstrated the beneficial prognosis of chromosomal 1p/19q co-deletion in these tumours. 2016 6. Observational study Staedtke V, Dzaye ODA, Holdhoff M. Actionable Molecular Biomarkers in Primary Brain Tumors. Trends Cancer. 2016;2(7):338-49. of actionable biomarkers available in the diagnosis of brain tumours. (i) MGMT promoter methylation as a prognostic and predictive marker in glioblastoma; (ii) codeletion of 1p and 19q differentiating oligodendrogliomas from astrocytomas; (iii) IDH1/2 mutations; and (iv) select mutations. 2016 7. Observational study Rare Cancers Australia: Just a Little More Time Rare Cancers Update Report. 2016 A review of available cancer data investigating the disparities existing for incidence, mortality and survival across the cancer spectrum. The study provided a definition for rare 2016
Somatic_Gene_Testing_(Web_AccessibleVersion2).docx